Benzinga··Vandana SinghRoche's Breast Cancer Drug Falls Short in Pivotal Trial, Stock Drops 5%
Roche's giredestrant failed to meet primary endpoint in Phase 3 breast cancer trial, causing 5% stock decline. Company plans adjuvant trial readout in 2027.
LLYNVORHHBYclinical trial failurePhase 3 trial